Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
AJR Am J Roentgenol
    February 2024
  1. PANIGRAHI B
    Editorial Comment: Utilization of Radiomics to Identify HER2-Low Breast Cancer.
    AJR Am J Roentgenol. 2024 Feb 14. doi: 10.2214/AJR.24.30953.
    >> Share

    January 2024
  2. PENG Y, Zhang X, Qiu Y, Li B, et al
    Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
    AJR Am J Roentgenol. 2024 Jan 24. doi: 10.2214/AJR.23.30603.
    >> Share

  3. GERLACH K
    Editorial Comment: Managing Breast Imaging Follow-Up After a Prior Breast Cancer Diagnosis.
    AJR Am J Roentgenol. 2024 Jan 10. doi: 10.2214/AJR.23.30772.
    >> Share

  4. IGARASHI T
    Editorial Comment: What Is the Utility of T2 Signal Intensity in Patients With HER2-Positive Breast Cancer?
    AJR Am J Roentgenol. 2024 Jan 10. doi: 10.2214/AJR.23.30785.
    >> Share

  5. LANGMAN EL, Johnson KS, Dinome ML
    Retained Biopsy Site Markers After Breast Lesion Surgical Resection: Associations With Residual Malignancy.
    AJR Am J Roentgenol. 2024;222:e2329670.
    >> Share

  6. BUTLER RS
    Editorial Comment: Artificial Intelligence May Help Define Screening Strategies in Patients With Dense Breasts.
    AJR Am J Roentgenol. 2024;222:e2330042.
    >> Share

    December 2023
  7. DO D, Mercaldo S, Bahl M
    Performance Metrics of Screening Digital Breast Tomosynthesis Based on Years Since a Prior Breast Cancer Diagnosis.
    AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30419.
    >> Share

  8. DONTCHOS BN, Lobbes MBI, Rahbar H
    Reply to "Cost-Effectiveness of Breast Cancer Staging Modalities: Is There a Role for MDCT in Low- and Moderate-Income Countries?".
    AJR Am J Roentgenol. 2023 Dec 6. doi: 10.2214/AJR.23.30619.
    >> Share

  9. BITENCOURT AGV, Felipe VC, Barbosa PNVP
    Cost-Effectiveness of Breast Cancer Staging Modalities: Is There a Role for MDCT in Low- and Moderate-Income Countries?
    AJR Am J Roentgenol. 2023 Dec 6. doi: 10.2214/AJR.23.30480.
    >> Share

  10. GRIMM LJ
    Beyond the AJR: Patient Knowledge About the Risk of Dense Breasts Is Lacking.
    AJR Am J Roentgenol. 2023;221:850.
    >> Share

    November 2023
  11. CORINES MJ, Sogani J, Hogan MP, Mango VL, et al
    The Role of Contrast-Enhanced Mammography After Cryoablation of Breast Cancer.
    AJR Am J Roentgenol. 2023 Nov 29. doi: 10.2214/AJR.23.30250.
    >> Share

  12. CHOU SS
    Editorial Comment: The Time Is Almost Ripe to Mainstream Diffusion in Routine Breast MRI.
    AJR Am J Roentgenol. 2023 Nov 1. doi: 10.2214/AJR.23.30445.
    >> Share

    October 2023
  13. GULLO RL, Partridge SC, Shin HJ, Thakur SB, et al
    Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.
    AJR Am J Roentgenol. 2023 Oct 18. doi: 10.2214/AJR.23.29933.
    >> Share

  14. MANN RM, Teuwen J
    Beyond the AJR: A Breakthrough in the Use of Artificial Intelligence for Mammography in Screening for Breast Cancer.
    AJR Am J Roentgenol. 2023 Oct 18. doi: 10.2214/AJR.23.30359.
    >> Share

  15. REICHMAN MB, McMahon P, Dwyer M, Chang SJ, et al
    Bleeding Events After Image-Guided Breast Biopsies: Comparison of Patients Temporarily Discontinuing Versus Maintaining Antithrombotic Therapy During Biopsy.
    AJR Am J Roentgenol. 2023;221:438-449.
    >> Share

    September 2023
  16. BARR RG
    Spatial Resolution Versus Contrast Resolution in Breast Ultrasound.
    AJR Am J Roentgenol. 2023 Sep 27:1. doi: 10.2214/AJR.23.29516.
    >> Share

    August 2023
  17. LAWHN-HEATH C
    Editorial Comment: Closing the Gap-Emerging Role of Estrogen Receptor-Targeted PET in Invasive Lobular Carcinoma.
    AJR Am J Roentgenol. 2023;221:239.
    >> Share

    July 2023
  18. LEE SE, Yoon JH, Son NH, Han K, et al
    Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound.
    AJR Am J Roentgenol. 2023 Jul 26. doi: 10.2214/AJR.23.29655.
    >> Share

  19. BITENCOURT AGV, Barbosa PNVP, Chojniak R
    Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device.
    AJR Am J Roentgenol. 2023 Jul 5:1-2. doi: 10.2214/AJR.23.29421.
    >> Share

  20. WEAVER OO, Kornecki A, Yang WT
    Reply to: "Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device".
    AJR Am J Roentgenol. 2023 Jul 5:2. doi: 10.2214/AJR.23.29476.
    >> Share

    June 2023
  21. DEIPOLYI AR, Ward RC, Riaz A, Vogl TJ, et al
    Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2023 Jun 28. doi: 10.2214/AJR.23.29454.
    >> Share

    May 2023
  22. PHILPOTTS LE
    Beyond the AJR: Patient Cost-Sharing Adversely Affects Adherence to Downstream Imaging After Mammography Screening.
    AJR Am J Roentgenol. 2023 May 31. doi: 10.2214/AJR.23.29685.
    >> Share

  23. HE P, Chen W, Bai MY, Li J, et al
    Deep Learning-Based Computer-Aided Diagnosis for Breast Lesion Classification on Ultrasound: A Prospective Multicenter Study of Radiologists Without Breast Ultrasound Expertise.
    AJR Am J Roentgenol. 2023 May 24. doi: 10.2214/AJR.23.29328.
    >> Share

  24. PHILPOTTS L
    Editorial Comment: Digital Breast Tomosynthesis Helps Optimize Use of BI-RADS Category 3 in Patients With a Personal History of Breast Cancer.
    AJR Am J Roentgenol. 2023 May 3. doi: 10.2214/AJR.23.29547.
    >> Share

  25. KIETURAKIS AJ, Hernandez OJ, Gao Y
    Mammary Adenoid Cystic Carcinoma: Improving Preoperative Size Assessment With MRI.
    AJR Am J Roentgenol. 2023 May 3. doi: 10.2214/AJR.23.29272.
    >> Share

    April 2023
  26. DONTCHOS BN, Rahbar H
    Cost-Effectiveness of Breast Cancer Staging Modalities: Counterpoint-Breast MRI Can be Cost-Effective for Breast Cancer Staging, Particularly in This Era of Treatment De-Escalation.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29501.
    >> Share

  27. LOBBES MBI, Essers BAB
    Cost-Effectiveness of Breast Cancer Staging Modalities: Point-Contrast-Enhanced Mammography as an Alternative to Breast MRI for Preoperative Staging in Patients with Breast Cancer.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29337.
    >> Share

  28. OFFIT LR, Chikarmane SA, Lacson RC, Giess CS, et al
    Frequency and Outcomes of BI-RADS Category 3 Assessments in Patients With a Personal History of Breast Cancer: Full-Field Digital Mammography Versus Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023 Apr 12. doi: 10.2214/AJR.23.29067.
    >> Share

  29. MENDELSON EB
    Beyond the AJR: Supplemental Ultrasound Screening Complements Digital Breast Tomosynthesis in Cancer Detection.
    AJR Am J Roentgenol. 2023 Apr 5. doi: 10.2214/AJR.23.29364.
    >> Share

    March 2023
  30. COVINGTON MF, Hoffman JM, Morton KA, Buckway B, et al
    Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas.
    AJR Am J Roentgenol. 2023 Mar 15. doi: 10.2214/AJR.22.28809.
    >> Share

  31. MEMA E, Lane EG, Drotman MB, Eisen CS, et al
    Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
    AJR Am J Roentgenol. 2023 Mar 8. doi: 10.2214/AJR.22.28970.
    >> Share

  32. BURKE CJ, Schonberger A, Friedman EB, Berman RS, et al
    Image-Guided Radar Reflector Localization for Small Soft-Tissue Lesions in the Musculoskeletal System.
    AJR Am J Roentgenol. 2023;220:399-406.
    >> Share

    February 2023
  33. PIRES-GONCALVES L
    Editorial Comment: Abbreviated MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment-One Step Forward in an Important Research Pathway.
    AJR Am J Roentgenol. 2023 Feb 22:9. doi: 10.2214/AJR.23.29167.
    >> Share

  34. CHOU SS
    Editorial Comment: Ultrafast MRI for Ductal Carcinoma In Situ-Potential for Imaging Biomarkers and Abbreviated MRI.
    AJR Am J Roentgenol. 2023 Feb 22:11. doi: 10.2214/AJR.23.29153.
    >> Share

  35. TANG WJ, Chen SY, Hu WK, Li XL, et al
    Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists.
    AJR Am J Roentgenol. 2023 Feb 8. doi: 10.2214/AJR.22.28686.
    >> Share

  36. MICELI R, Gao Y, Qian K, Heller SL, et al
    Predicting Upgrade of Ductal Carcinoma in Situ to Invasive Cancer at Breast Surgery With Ultrafast Imaging.
    AJR Am J Roentgenol. 2023 Feb 8. doi: 10.2214/AJR.22.28698.
    >> Share

  37. GREENSTEIN JA, Friedewald SM
    Beyond the AJR: Potential Effects of Insurance Coverage Mandates for Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023;220:304.
    >> Share

  38. KORNECKI A, Bhaduri M, Khan N, Nachum IB, et al
    Contrast-Enhanced Mammography-Guided Breast Biopsy: Single Center Experience.
    AJR Am J Roentgenol. 2023 Feb 1. doi: 10.2214/AJR.22.28780.
    >> Share

    January 2023
  39. WANG S, Sun Y, You C, Jiang T, et al
    Association of Clinical Factors and Degree of Early Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
    AJR Am J Roentgenol. 2023 Jan 25. doi: 10.2214/AJR.22.28769.
    >> Share

  40. SINHA P, Lamonica DM
    Beyond the AJR: (99m)Tc-MDP Bone Scintigraphy-Has It Met Its Match?
    AJR Am J Roentgenol. 2023 Jan 11. doi: 10.2214/AJR.23.28978.
    >> Share

  41. WANG LC, Philip M, Bhole S, Rao S, et al
    Pathologic Outcomes in Single Versus Multiple Areas of Architectural Distortion on Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023;220:50-62.
    >> Share

    December 2022
  42. SEILER SJ, Neuschler EI, Butler RS, Lavin PT, et al
    Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study.
    AJR Am J Roentgenol. 2022 Dec 7. doi: 10.2214/AJR.22.28470.
    >> Share

    November 2022
  43. LEE YS, Cheng YY, Yeh DM
    Factors That May Influence Contrast-Enhanced Digital Mammography Findings.
    AJR Am J Roentgenol. 2022 Nov 30:1. doi: 10.2214/AJR.22.28236.
    >> Share

  44. VAN NIJNATTEN TJA, Lobbes MBI, Cozzi A, Patel BK, et al
    Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 Nov 30. doi: 10.2214/AJR.22.28567.
    >> Share

  45. MURILLO NDB, Rueda MA, Ortegon JDC
    Contrast-Enhanced Mammography, a Diagnostic and Follow-Up Method With Potential Research Opportunities.
    AJR Am J Roentgenol. 2022 Nov 16:1. doi: 10.2214/AJR.22.28228.
    >> Share

  46. YOON JH, Kim EK
    Beyond the AJR: Deep Learning Model for Risk-Based Breast Cancer Screening.
    AJR Am J Roentgenol. 2022 Nov 9. doi: 10.2214/AJR.22.28703.
    >> Share

  47. WEAVER OO, Yang WT, Scoggins ME, Adrada BE, et al
    Challenging Contrast-Enhanced Mammography-Guided Biopsies: Practical Approach Using Real-Time Multimodality Imaging and a Proposed Procedural Algorithm.
    AJR Am J Roentgenol. 2022 Nov 2. doi: 10.2214/AJR.22.28572.
    >> Share

    September 2022
  48. AHLAWAT S, Debs P, Amini B, Lecouvet FE, et al
    Clinical Applications and Controversies of Whole-Body MRI: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 Sep 28. doi: 10.2214/AJR.22.28229.
    >> Share

  49. NGUYEN DL, Boron A, Oluyemi ET, Myers KS, et al
    Comparison of Diagnostic Mammography-Guided Biopsy and Digital Breast Tomosynthesis-Guided Biopsy of Suspicious Breast Calcifications: Results in 1354 Biopsies.
    AJR Am J Roentgenol. 2022 Sep 14. doi: 10.2214/AJR.22.28320.
    >> Share

  50. OLUYEMI ET, Ambinder EB
    Beyond the AJR: Racial and Ethnic Disparities in the Timeliness of Biopsy After Abnormal Screening Mammography.
    AJR Am J Roentgenol. 2022 Sep 7. doi: 10.2214/AJR.22.28458.
    >> Share

    August 2022
  51. LEE CU, Larson NB, Urban MW, Miller AL 2nd, et al
    Factors Associated With Ultrasound Color Doppler Twinkling by Breast Biopsy Markers: In Vitro and Ex Vivo Evaluation of 35 Commercially Available Markers.
    AJR Am J Roentgenol. 2022 Aug 31. doi: 10.2214/AJR.22.28107.
    >> Share

  52. NIDA BA, Rooney TB, Miller MM
    Utility of MRI-Directed Contrast-Enhanced Mammography for Biopsy Planning of Suspicious MRI-Detected Breast Lesions.
    AJR Am J Roentgenol. 2022 Aug 24. doi: 10.2214/AJR.22.28055.
    >> Share

    July 2022
  53. HUNT KN, Conners AL, Samreen N, Rhodes D, et al
    PPV of the Molecular Breast Imaging Lexicon.
    AJR Am J Roentgenol. 2022 Jul 20. doi: 10.2214/AJR.21.27047.
    >> Share

  54. CHEN JX, Deng F
    Screening Mammography Utilization Among Women With Visual or Hearing Impairment: Results From the 2019 National Health Interview Survey.
    AJR Am J Roentgenol. 2022 Jul 13. doi: 10.2214/AJR.22.27992.
    >> Share

  55. DELEAU F, Linck PA, Brouste V, Thomassin-Naggara I, et al
    Impact of Obtaining a Digital Breast Tomosynthesis (DBT) Spot Compression View on Assessment of Equivocal DBT Findings.
    AJR Am J Roentgenol. 2022;219:37-45.
    >> Share

  56. VILLA-CAMACHO JC, Bahl M
    Management of Architectural Distortion on Digital Breast Tomosynthesis With Nonmalignant Pathology at Biopsy.
    AJR Am J Roentgenol. 2022;219:46-54.
    >> Share

    June 2022
  57. WOODARD S
    Editorial Comment: Evidence Supporting Contrast-Enhanced Mammography (CEM) for Monitoring Neoadjuvant Chemotherapy Response and Showing the Potential of Delayed CEM.
    AJR Am J Roentgenol. 2022 Jun 29. doi: 10.2214/AJR.22.28128.
    >> Share

  58. BERNARDI D, Vatteroni G, Acquaviva A, Valentini M, et al
    Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    AJR Am J Roentgenol. 2022 Jun 22. doi: 10.2214/AJR.22.27756.
    >> Share

  59. GONG AJ, Nguyen DL, Lee EE, Mullen LA, et al
    Comparison of Outcomes for One-View Asymmetries Recalled From Digital Breast Tomosynthesis Versus Full-Field Digital Mammography Screening Examinations.
    AJR Am J Roentgenol. 2022 Jun 15. doi: 10.2214/AJR.22.27820.
    >> Share

    May 2022
  60. LAMB LR, Lehman CD, Gastounioti A, Conant EF, et al
    Reply to "The Matrix Is Not Ready for Screening Mammography".
    AJR Am J Roentgenol. 2022 May 25:2-3. doi: 10.2214/AJR.22.27502.
    >> Share

  61. BRENNER RJ
    The Matrix Is Not Ready for Screening Mammography.
    AJR Am J Roentgenol. 2022 May 25:1-2. doi: 10.2214/AJR.22.27423.
    >> Share

  62. BERGMANN LL, Hobbs S
    Beyond the AJR: The Impact of Screening Population in Lung Cancer Overdiagnosis.
    AJR Am J Roentgenol. 2022 May 25. doi: 10.2214/AJR.22.27970.
    >> Share

  63. LANE EG, Eisen CS, Drotman MB, Dodelzon K, et al
    Time for Resolution of COVID-19 Vaccine-Related Lymphadenopathy and Associated Factors.
    AJR Am J Roentgenol. 2022 May 18. doi: 10.2214/AJR.22.27687.
    >> Share

  64. LAWSON MB, Herschorn SD, Sprague BL, Buist DSM, et al
    Imaging Surveillance Options for Individuals With a Personal History of Breast Cancer: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 May 11. doi: 10.2214/AJR.22.27635.
    >> Share

    April 2022
  65. DONTCHOS BN, Wang GX
    Beyond the AJR: Impact of Routine Breast Cancer Risk Assessment on Screening Mammography Adherence Among Women in Racial and Ethnic Minority Groups.
    AJR Am J Roentgenol. 2022 Apr 20:1. doi: 10.2214/AJR.21.27107.
    >> Share

  66. LOWRY KP
    Breast Imaging in Older Patients: Counterpoint-Navigating Uncertainty.
    AJR Am J Roentgenol. 2022 Apr 13. doi: 10.2214/AJR.22.27733.
    >> Share

    March 2022
  67. GUIRGUIS MS, Adrada BE, Scoggins ME, Moseley TW, et al
    The Challenging Image-Guided Preoperative Breast Localization: A Modality-Based Approach.
    AJR Am J Roentgenol. 2022;218:423-434.
    >> Share

    February 2022
  68. LU AH, Zuley ML, Berg WA
    Enhancing Cherry Hemangioma: A Mimic for Breast Cancer on Contrast-Enhanced Mammography.
    AJR Am J Roentgenol. 2022 Feb 9. doi: 10.2214/AJR.22.27363.
    >> Share

  69. MULLEN LA, Ambinder EB
    Beyond the AJR: Validation of an Artificial Intelligence Breast Cancer Risk Assessment Model Across Diverse International Cohorts.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.22.27436.
    >> Share

  70. DESTOUNIS S
    Beyond the AJR: Screening Mammography Over Age 75.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.22.27447.
    >> Share

  71. DONTCHOS BN, Lehman CD
    Reply to "Strategies Used to Reduce the Time of Diagnosis in Screening Mammography".
    AJR Am J Roentgenol. 2022;218:389-390.
    >> Share

    January 2022
  72. HO EL, Kim MJ, Wilkinson LS, Given-Wilson R, et al
    The Global Reading Room: Recovery of Breast Cancer Screening Services After the COVID-19 Pandemic First Wave.
    AJR Am J Roentgenol. 2022 Jan 26. doi: 10.2214/AJR.22.27416.
    >> Share

  73. KHANANI S
    Editorial Comment: Artificial Intelligence in Mammography-Our New Reality.
    AJR Am J Roentgenol. 2022 Jan 12. doi: 10.2214/AJR.22.27345.
    >> Share

  74. LAMB LR, Lehman CD, Gastounioti A, Conant EF, et al
    Artificial Intelligence (AI) for Screening Mammography, From the AI Special Series on AI Applications.
    AJR Am J Roentgenol. 2022 Jan 12. doi: 10.2214/AJR.21.27071.
    >> Share

  75. D'ALESSIO D
    Editorial Comment: Move Forward to Bring Patients Back for Breast Cancer Screening.
    AJR Am J Roentgenol. 2022 Jan 5. doi: 10.2214/AJR.21.27247.
    >> Share

  76. LAMB LR, Bahl M
    Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions.
    AJR Am J Roentgenol. 2022;218:186-187.
    >> Share

    December 2021
  77. AMBINDER EB, Myers KS, Oluyemi E, Panigrahi B, et al
    Reply to "Women Successfully Treated for Breast Cancer Can Return Immediately to Annual Screening".
    AJR Am J Roentgenol. 2021 Dec 29:1-2. doi: 10.2214/AJR.21.27061.
    >> Share

  78. KOPANS DB
    Women Successfully Treated for Breast Cancer Can Return Immediately to Annual Screening.
    AJR Am J Roentgenol. 2021 Dec 29:1. doi: 10.2214/AJR.21.27030.
    >> Share

  79. GONZALEZ-GOMEZ S, Rueda-Ruiz N, Palazuelos G
    Strategies Used to Reduce the Time of Diagnosis in Screening Mammography.
    AJR Am J Roentgenol. 2021 Dec 29:1. doi: 10.2214/AJR.21.27042.
    >> Share

  80. HAO M, Edmonds C, Nachiappan A, Conant E, et al
    Management Strategies for Patients Presenting With Symptomatic Lymphadenopathy and Breast Edema After Recent COVID-19 Vaccination.
    AJR Am J Roentgenol. 2021 Dec 29. doi: 10.2214/AJR.21.27118.
    >> Share

  81. NARANJO ID, Sogani J, Saccarelli C, Horvat JV, et al
    MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images.
    AJR Am J Roentgenol. 2021 Dec 22. doi: 10.2214/AJR.21.27022.
    >> Share

  82. NGUYEN DL, Ambinder EB, Myers KS, Mullen LA, et al
    COVID-19 Vaccine-Related Axillary Adenopathy on Breast Imaging: Follow-Up Recommendations and Histopathologic Findings.
    AJR Am J Roentgenol. 2021 Dec 22. doi: 10.2214/AJR.21.27162.
    >> Share

  83. POREMBKA JH, Seiler SJ, Sharifi A, Mootz A, et al
    Diagnostic Evaluation of Recalled Noncalcified Lesions Using Ultrasound Alone Versus Ultrasound Plus Additional Mammographic Views: A Prospective Study.
    AJR Am J Roentgenol. 2021 Dec 15. doi: 10.2214/AJR.21.26700.
    >> Share

  84. BHATT AA, Woodard GA, Lee CU
    Use of an Introducer for Radioactive Seed Localization of Targets Beyond the Length of Available Preloaded Needles.
    AJR Am J Roentgenol. 2021;217:1475.
    >> Share

  85. LEE SJ, Wahab RA, Sobel LD, Zhang B, et al
    Analysis of 612 Benign Papillomas Diagnosed at Core Biopsy: Rate of Upgrade to Malignancy, Factors Associated With Upgrade, and a Proposal for Selective Surgical Excision.
    AJR Am J Roentgenol. 2021;217:1299-1311.
    >> Share

    November 2021
  86. AMIR T, Hogan MP, Jacobs S, Sevilimedu V, et al
    Comparison of False-Positive Versus True-Positive Findings on Contrast-Enhanced Digital Mammography.
    AJR Am J Roentgenol. 2021 Nov 24. doi: 10.2214/AJR.21.26847.
    >> Share

  87. LEHMAN CD, Mercaldo SF, Wang GX, Dontchos BN, et al
    Screening Mammography Recovery After COVID-19 Pandemic-Related Closures: Associations of Facility Access and Racial and Ethnic Screening Disparities.
    AJR Am J Roentgenol. 2021 Nov 24. doi: 10.2214/AJR.21.26890.
    >> Share

    October 2021
  88. SADIGH G, Lowry KP
    Beyond the AJR: Screening Breast MRI Is Associated With Substantial Financial Burden in Women With Private Insurance Due to Lack of Coverage by the Affordable Care Act.
    AJR Am J Roentgenol. 2021 Oct 20:1. doi: 10.2214/AJR.21.26956.
    >> Share

  89. CARNAHAN MB, Pockaj B, Pizzitola V, Giurescu ME, et al
    Contrast-Enhanced Mammography for Newly Diagnosed Breast Cancer in Women With Breast Augmentation: Preliminary Findings.
    AJR Am J Roentgenol. 2021;217:855-856.
    >> Share

  90. AMBINDER EB, Plotkin A, Euhus D, Mullen LA, et al
    Tomosynthesis-Guided Vacuum-Assisted Breast Biopsy of Architectural Distortion Without a Sonographic Correlate: A Retrospective Review.
    AJR Am J Roentgenol. 2021;217:845-854.
    >> Share

  91. CHUNG HL, Sun J, Leung JWT
    Breast Cancer Skip Metastases: Frequency, Associated Tumor Characteristics, and Role of Staging Nodal Ultrasound in Detection.
    AJR Am J Roentgenol. 2021;217:835-844.
    >> Share

    September 2021
  92. VIERS KN, Hunt LD
    Lymph Node Staging in Newly Diagnosed Breast Cancer: Point-Preoperative Staging Axillary Ultrasound is Valuable in the Contemporary Evaluation of Newly Diagnosed Breast Cancer.
    AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26812.
    >> Share

  93. BHOLE S, Friedewald SM
    Lymph Node Staging in Newly Diagnosed Breast Cancer: Counterpoint-Sentinel Biopsy Surpasses Axillary Imaging in Early-Stage Cancers, But Is the Sun Setting on This Controversy?
    AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26767.
    >> Share

  94. WOLFSON S, Heller SL, Gao Y
    Multiple Bilateral Circumscribed Masses (MBCM) at Screening Breast Ultrasound (US): Outcomes of New or Enlarging Masses at Follow-up.
    AJR Am J Roentgenol. 2021 Sep 22. doi: 10.2214/AJR.21.26520.
    >> Share

  95. SANDERS LM
    Editorial Comment: MRI is Useful in a High-Risk Patient Cohort Prior to Prophylactic Mastectomy, Obviating Sentinel Node Sampling in Those with Negative Studies.
    AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26795.
    >> Share

  96. OLUYEMI E
    Editorial Comment: Offering Immediate Screening Mammography Interpretation May Be an Effective way to Reduce the Racial and Ethnic Disparity Gap in the Time to Diagnostic Follow-up.
    AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26798.
    >> Share

  97. TALIAFERRO AS, Price ER, Hayward JH, Wong J, et al
    Utility and Outcomes of Pre-Operative Screening Breast MRI for Planned Bilateral Prophylactic Mastectomy in High-Risk Patients.
    AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26561.
    >> Share

    August 2021
  98. YOON JH, Kim EK, Kim GR, Han K, et al
    Mammographic Surveillance After Breast Conserving Therapy: Impact of Digital Breast Tomosynthesis and Artificial Intelligence-Based Computer-Aided Detection.
    AJR Am J Roentgenol. 2021 Aug 11. doi: 10.2214/AJR.21.26506.
    >> Share

  99. GRIMM LJ, Mango VL, Harvey JA, Plecha DM, et al
    Implementation of Abbreviated Breast MRI for Screening: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2021 Aug 11. doi: 10.2214/AJR.21.26349.
    >> Share

    July 2021
  100. CHUNG HL, Tso HH, Middleton LP, Sun J, et al
    Axillary Nodal Metastases in Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma: Comparison of Node Detection and Morphology by Ultrasound.
    AJR Am J Roentgenol. 2021 Jul 28. doi: 10.2214/AJR.21.26135.
    >> Share

  101. BARR RG, DeSivestri A, Golatta M
    Outcomes of Return to Routine Screening for BI-RADS 3 Lesions Detected at Supplemental Automated Whole-Breast Ultrasound in Women with Dense Breasts: A Prospective Study.
    AJR Am J Roentgenol. 2021 Jul 14. doi: 10.2214/AJR.21.26180.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016